Cogent Biosciences (COGT) Other Accumulated Expenses (2017 - 2026)

Cogent Biosciences (COGT) has 9 years of Other Accumulated Expenses data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 281.4% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 281.4% increase from a year earlier, with the FY2025 full-year figure at $6.7 million, up 1708.31% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.8 million, down from $6.7 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for COGT reached as high as $6.7 million in Q4 2025 and fell as low as $252000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.1 million across 5 years, with a median of $496000.0 in 2023.
• Across the five-year window, Other Accumulated Expenses tumbled 68.23% in 2023 and surged 1708.31% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $404000.0 in 2022, then grew by 9.16% to $441000.0 in 2023, then slipped by 15.42% to $373000.0 in 2024, then jumped by 1708.31% to $6.7 million in 2025, then slumped by 72.63% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $1.8 million in Q1 2026, $6.7 million in Q4 2025, and $1.3 million in Q3 2025.